Securities code: Ningbo Menovo Pharmaceutical Co.Ltd(603538) securities abbreviation: Ningbo Menovo Pharmaceutical Co.Ltd(603538) Announcement No.: 2022017 bond Code: 113618 bond abbreviation: Meinuo convertible bond
Ningbo Menovo Pharmaceutical Co.Ltd(603538)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Abnormal fluctuation of stock trading: Ningbo Menovo Pharmaceutical Co.Ltd(603538) (hereinafter referred to as “the company”) shares have deviated from the closing price by more than 20% in three consecutive trading days on March 4, March 7 and March 8, 2022, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange.
After the company’s self-examination and written consultation with the controlling shareholder and actual controller for verification, as of the disclosure date of this announcement, the company, the controlling shareholder and the actual controller have no material information that should be disclosed but not disclosed. Please make rational decisions and pay attention to investment risks.
1、 Details of abnormal fluctuations in stock trading
The cumulative deviation of the closing price of the company’s shares from the value on March 4, March 7 and March 8, 2022 is more than 20%, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange.
2、 Relevant information concerned and verified by the company
In view of the abnormal fluctuation of the company’s stock trading, the company has conducted self-examination on relevant matters and consulted the controlling shareholder and actual controller of the company in writing for verification. The relevant information is explained as follows:
(I) production and operation
According to the company’s self inspection, the company’s current production and operation is normal, the internal and external business environment has not changed significantly, and there is no other major information that should be disclosed but not disclosed.
(II) major events
After the company’s self-examination and written consultation and verification with the controlling shareholders and actual controllers, as of the disclosure date of this announcement, the company, the controlling shareholders and actual controllers have no major information that should be disclosed but not disclosed, including but not limited to the major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset stripping, asset injection Share repurchase, equity incentive, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major issues.
(III) media reports, market rumors and hot concepts
Recently, some investors have paid attention to “whether the company involves SM1, SM2, T17 and pf-07321332 related intermediate products”. After verification by the company, the relevant business is explained as follows: at present, the company has realized commercial production of intermediate products SM1 and SM2, but the revenue accounts for a relatively small proportion, which does not have a significant impact on the company’s performance. At present, the orders undertaken by the company do not involve T17 and pf-07321332. The company is promoting the application for international MPP authorization, but it has not obtained relevant authorization as of the submission date of this announcement, and there is still great uncertainty about whether it can obtain authorization in the future.
(IV) other stock price sensitive information
It is verified that the company’s directors, supervisors, senior managers, controlling shareholders, actual controllers and their persons acting in concert and other important shareholders did not buy or sell the company’s shares during the abnormal fluctuation of this stock trading. The company has not found any other major events that may have a great impact on the company’s share price.
3、 Relevant risk tips
The daily closing price of the company’s shares deviated by more than 20% in three consecutive trading days on March 4, March 7 and March 8, 2022. The actual fluctuation range of the share price excluding the overall factors of the market and the sector is large. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that up to now, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules of Shanghai Stock Exchange For the information that may have a great impact on the trading price of the company’s shares and their derivatives, the information disclosed by the company in the early stage does not need to be corrected or supplemented.
The information disclosure media designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN) According to China Securities News, Shanghai Securities News and securities times, the relevant information of the company shall be subject to the announcement published by the company in the above designated media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Ningbo Menovo Pharmaceutical Co.Ltd(603538) board of directors March 9, 2022
